WEST PALM BEACH, Fla., July 11, 2025 (GLOBE NEWSWIRE) -- Solitron Devices, Inc. (OTC Pink: SODI) (“Solitron” or the “Company”) is pleased to announce fiscal 2026 first quarter results. FISCAL 2026 FIRST QUARTER HIGHLIGHTS – Net sales decreased 32% to approximately $2.70 million in the fiscal 2026 first quarter versus $3.97 million in the fiscal 2025 first quarter.Net bookings increased 37% to $2.80 million in the fiscal 2026 first quarter versus $2.04 million in the prior year first quarter.Backlog increas ...

Industry Overview - The Zacks Manufacturing-Tools & Related Products industry includes companies that develop and distribute various tools and technology solutions, serving multiple sectors such as industrial, commercial, oil & gas, and automotive [3] - The industry is currently facing challenges due to a slowdown in the manufacturing sector, with the Manufacturing Purchasing Manager's Index at 49% in June, indicating contraction [4] - The New Orders Index has also been in contraction for five consecutive months, registering 46.4% in June [4] Current Challenges - The industry is experiencing input cost inflation and supply-chain issues, which are negatively impacting profitability and margins [5] - The Supplier Deliveries Index indicates slower deliveries for the seventh consecutive month, further complicating the operational landscape [5] - A shortage of skilled labor in the United States is also a significant challenge for the industry [1] Strategic Responses - Companies in the industry are focusing on cost-control measures and investments in product development to remain competitive [2] - Initiatives include streamlining operational structures, optimizing supply networks, and implementing effective pricing policies to manage costs [5] - Continuous innovation and product upgrades are seen as essential for long-term growth, although they may lead to highly leveraged balance sheets [6] Performance Metrics - The Zacks Manufacturing-Tools & Related Products industry currently holds a Zacks Industry Rank of 163, placing it in the bottom 34% of 246 Zacks industries, indicating weak prospects [7][8] - The industry's earnings estimates for 2025 have decreased by 7.3% over the past year, reflecting analysts' diminishing confidence in earnings growth potential [9] - Over the past year, the industry has underperformed compared to the sector and the S&P 500, growing only 7.7% versus 14.8% and 12.4% respectively [11] Valuation Insights - The industry is currently trading at a forward P/E ratio of 17.92X, which is below the S&P 500's 22.75X and the sector's 20.09X [14] - Historical trading ranges for the industry have been between 11.65X and 22.13X over the past five years, with a median of 18.55X [14] Notable Companies - **Stanley Black & Decker, Inc. (SWK)**: Focused on tools and engineered fastening systems, the company has shown solid momentum in its Tools & Outdoor segment, particularly in its DEWALT business. It has reported better-than-expected results in the last four quarters, with an average earnings surprise of 18.4% [19][20] - **Core & Main, Inc. (CNM)**: Provides water and fire protection products, benefiting from increased demand and recent acquisitions. Its fiscal 2026 earnings estimates have been revised upward by 1.2% in the past 60 days [23][24] - **Kennametal Inc. (KMT)**: Specializes in high-speed metal cutting tools and has seen improved supply chain conditions and increased OEM build rates in aerospace markets. The company has consistently surpassed earnings estimates, with an average surprise of 27% [26][27]

Core Viewpoint - Moderna has experienced a significant decline in stock performance and sales due to waning demand for its coronavirus vaccine, losing over 90% of its value since its peak in 2021 [1][2][7] Company Background - Moderna initially gained prominence during the pandemic, generating up to $18.4 billion in annual revenue from its coronavirus vaccine, leading to substantial profits [4] - The company has since faced challenges as vaccine demand decreased, and its RSV vaccine sales have also underperformed [5] Cost Management and R&D Focus - In response to declining sales, Moderna has initiated a cost realignment plan aiming to reduce GAAP operating costs by up to $1.7 billion by 2027 [6] - The company is prioritizing research and development, with plans to launch as many as 10 new products in the next three years, although these launches are not guaranteed [6] Future Product Pipeline - Moderna anticipates having around 10 products on the market in 10 years, including several cancer vaccines and a cytomegalovirus vaccine, along with potential respiratory virus vaccines [11] - The company has a strong success rate in late-stage trials, with an 83% probability of success in phase 3 trials compared to the industry average of 69% [12] Revenue Projections - By 2028, Moderna expects to break even on an operating cash cost basis and generate $6 billion in revenue, with new product launches from 2026 to 2028 projected to yield a compounded annual growth rate of 25% or more [12] - Even with partial success in product launches, Moderna could achieve significant revenue growth over the next decade [13]

then the question is "how do I get users?"make something ppl want and get it in front of thempeople think the "hard" part is getting funding — no the hard part is making something ppl want!of course funding will be hard if you haven't made something that ppl use lol ...

But what's very relevant to understand is the the the technology potential is increasing very significantly with compute. Yeah. With with the with the evolution of computing.But also you're finding always every day new ways of using this technology which means that the products need to evolve really fast and the products that were useful yesterday will not be useful tomorrow. And so basically what you need to optimize for is adaptation and and the speed of evolution. not necessarily having a product that is ...

Mr. Hunter brings more than 40 years of experience building and leading commercial organizations in the biopharmaceutical industry, including leadership roles at Validus Pharmaceuticals, Relialab and Novartis Led launch of Tonix Medicines, acquisition of migraine assets Zembrace® SymTouch® and Tosymra®, and recruitment of commercial leadership team Appointment strengthens commercial strategy and governance as Tonix prepares for potential launch of TNX-102 SL for fibromyalgia this year CHATHAM, N.J., June 13 ...

Through simulation-led product development, Turbotech becomes first company to successfully run a scalable turboprop out of a cryogenic hydrogen tank/ Key Highlights Leveraging Ansys simulation to validate its innovative design, Turbotech's hydrogen turbine propulsion system can operate with high efficiency and produce zero carbon emissions for light aviation Turbotech integrates Ansys across its designs — from component to system — creating a digital thread that drives significant time and cost savings wh ...

If I'm inside a behemoth like I'm inside Amazon and Amazon has a product in our category, do you think the employees working on this are worried if they will have a job in six months if they don't ship a great product. If we had shipped the same quality product that some of these hyperscalers have shipped, we'd be out of the market a year ago. But they probably still have their jobs right now.A startup has existential dread on whether or not they can survive if they don't ship fast. ...

SPX Technologies (SPXC) FY Conference Summary Company Overview - SPX Technologies operates in niche industrial applications across HVAC and detection and measurement markets [2][4] - The company has a strong track record for margin expansion and has executed 16 acquisitions over the past four and a half years [2][17] - SPX is predominantly North American, with about 83% of its revenue from this region, but is expanding in Europe and Asia [4] Core Business Segments HVAC Segment - HVAC constitutes about two-thirds of SPX's business, generating approximately $1.5 billion in revenue this year [9][31] - The segment has a margin of around 22% and is characterized by a significant portion of replacement revenue, approximately 60% [10][32] - SPX focuses on engineered products in high-tech niches, avoiding competition with larger players like Carrier and Trane [11] Detection and Measurement Segment - This segment includes technologies for underground inspections and monitoring, with a revenue target of around $710 million [34][37] - SPX is a leader in outdoor technologies, particularly in precision locators and inspection robots for water and gas infrastructure [8][34] Financial Performance and Growth Strategy - SPX aims to double its EBITDA from $483 million to approximately $1 billion over the next four to five years [12][18] - The company has a strong focus on strategic M&A, with a capital allocation strategy that prioritizes growth investments over dividends [26][39] - SPX has a robust balance sheet, with a pro forma leverage ratio of around 1.9 after recent acquisitions [40] Market Dynamics and Future Outlook - The company has seen double-digit organic growth driven by better product offerings, particularly in healthcare and institutional markets [56][57] - SPX is optimistic about entering the adiabatic and dry cooling tower markets, which could significantly expand its total addressable market (TAM) [61][62] - The company anticipates meaningful revenue opportunities from new products in the data center market by 2026 [66] Competitive Landscape - SPX competes with private companies in the cooling tower market but believes it has a competitive edge due to superior mechanical equipment [73][74] - The detection and measurement segment is expected to benefit from federal funding for infrastructure projects, particularly in transportation [75] Key Takeaways - SPX Technologies is well-positioned for growth in both HVAC and detection and measurement markets, with a clear strategy focused on engineered products and strategic acquisitions [2][17] - The company is leveraging its strong brand equity and market leadership to capture additional market share and drive revenue growth [10][11] - Future growth is expected to be supported by new product launches and increased federal funding for infrastructure projects [75]

CHATHAM, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP), a fully-integrated biotechnology company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals participated in a fireside chat at A.G.P.’s Annual Healthcare Company Showcase. A webcast of the presentation can be found under the IR Events tab of the Tonix website at www.tonixpharma.com. Tonix Pharmaceuticals H ...